Press Releases Items Per Page 102550 Year None201920182017201620152014 10-14-2019 Daré Bioscience to Participate in Two Upcoming Investor Conferences 10-10-2019 Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo 10-07-2019 Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference 09-11-2019 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics 09-09-2019 Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder 09-04-2019 Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference 08-14-2019 Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update 08-12-2019 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 08-08-2019 Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology 08-06-2019 Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 33
10-10-2019 Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
10-07-2019 Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference
09-11-2019 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics
09-09-2019 Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
09-04-2019 Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
08-12-2019 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
08-08-2019 Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
08-06-2019 Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
